CN100361943C - 2-(丁基-1-磺酰氨基)-n-[1(r)-(6-甲氧基吡啶-3-基)丙基]苯甲酰胺、其作为药物的用途以及包含所述化合物的药物制剂 - Google Patents

2-(丁基-1-磺酰氨基)-n-[1(r)-(6-甲氧基吡啶-3-基)丙基]苯甲酰胺、其作为药物的用途以及包含所述化合物的药物制剂 Download PDF

Info

Publication number
CN100361943C
CN100361943C CNB2004800060168A CN200480006016A CN100361943C CN 100361943 C CN100361943 C CN 100361943C CN B2004800060168 A CNB2004800060168 A CN B2004800060168A CN 200480006016 A CN200480006016 A CN 200480006016A CN 100361943 C CN100361943 C CN 100361943C
Authority
CN
China
Prior art keywords
methoxypyridine
butyl
benzamide
sulfonamido
propyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800060168A
Other languages
English (en)
Chinese (zh)
Other versions
CN1756728A (zh
Inventor
J·布伦德尔
H·格格莱因
K·维尔特
G·U·屈尔泽尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of CN1756728A publication Critical patent/CN1756728A/zh
Application granted granted Critical
Publication of CN100361943C publication Critical patent/CN100361943C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CNB2004800060168A 2003-03-18 2004-03-05 2-(丁基-1-磺酰氨基)-n-[1(r)-(6-甲氧基吡啶-3-基)丙基]苯甲酰胺、其作为药物的用途以及包含所述化合物的药物制剂 Expired - Fee Related CN100361943C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10312073A DE10312073A1 (de) 2003-03-18 2003-03-18 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3yl)-propyl]-benzamid, dessen Verwendung als Medikament sowie dieses enthaltende pharmazeutische Zubereitungen
DE10312073.4 2003-03-18

Publications (2)

Publication Number Publication Date
CN1756728A CN1756728A (zh) 2006-04-05
CN100361943C true CN100361943C (zh) 2008-01-16

Family

ID=32920928

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800060168A Expired - Fee Related CN100361943C (zh) 2003-03-18 2004-03-05 2-(丁基-1-磺酰氨基)-n-[1(r)-(6-甲氧基吡啶-3-基)丙基]苯甲酰胺、其作为药物的用途以及包含所述化合物的药物制剂

Country Status (21)

Country Link
EP (1) EP1606237A1 (https=)
JP (1) JP2006520343A (https=)
KR (1) KR20050110681A (https=)
CN (1) CN100361943C (https=)
AR (1) AR043622A1 (https=)
AU (1) AU2004222137A1 (https=)
BR (1) BRPI0408441A (https=)
CA (1) CA2519022A1 (https=)
DE (1) DE10312073A1 (https=)
HR (1) HRP20050815A2 (https=)
MA (1) MA27749A1 (https=)
MX (1) MXPA05009763A (https=)
MY (1) MY176510A (https=)
NO (1) NO20054472L (https=)
NZ (1) NZ542476A (https=)
PE (1) PE20050307A1 (https=)
RS (1) RS20050690A (https=)
RU (1) RU2333202C2 (https=)
TW (1) TW200500342A (https=)
WO (1) WO2004083157A1 (https=)
ZA (1) ZA200506328B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028845A1 (de) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
WO2007015775A2 (en) * 2005-07-22 2007-02-08 Merck & Co., Inc. Potassium channel inhibitors
EP2435407B1 (en) * 2009-05-29 2019-12-25 RaQualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088073A1 (de) * 2001-04-28 2002-11-07 Aventis Pharma Deutschland Gmbh Anthranilsäureamide, verfahren zu ihrer herstellung, ihre verwendung als antiarrhythmika sowie pharmazeutische zubereitungen davon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472053B1 (en) * 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088073A1 (de) * 2001-04-28 2002-11-07 Aventis Pharma Deutschland Gmbh Anthranilsäureamide, verfahren zu ihrer herstellung, ihre verwendung als antiarrhythmika sowie pharmazeutische zubereitungen davon

Also Published As

Publication number Publication date
PE20050307A1 (es) 2005-06-08
DE10312073A1 (de) 2004-09-30
TW200500342A (en) 2005-01-01
HK1086819A1 (en) 2006-09-29
RU2005132163A (ru) 2006-04-10
RS20050690A (sr) 2008-04-04
MY176510A (en) 2020-08-12
WO2004083157A1 (de) 2004-09-30
RU2333202C2 (ru) 2008-09-10
ZA200506328B (en) 2006-04-26
MA27749A1 (fr) 2006-02-01
MXPA05009763A (es) 2006-01-27
BRPI0408441A (pt) 2006-04-04
JP2006520343A (ja) 2006-09-07
NZ542476A (en) 2008-05-30
CN1756728A (zh) 2006-04-05
AU2004222137A1 (en) 2004-09-30
KR20050110681A (ko) 2005-11-23
AR043622A1 (es) 2005-08-03
NO20054472L (no) 2005-09-27
CA2519022A1 (en) 2004-09-30
HRP20050815A2 (en) 2006-09-30
EP1606237A1 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
CN100522937C (zh) 邻氨基苯甲酰胺类化合物、其制备方法、其作为抗心律不齐剂的应用及其药物制剂
CN100548300C (zh) 雷诺嗪在用于制备治疗心律失常药剂中的应用
KR20040102080A (ko) 새로운 갑상선 수용체 리간드
CN100361943C (zh) 2-(丁基-1-磺酰氨基)-n-[1(r)-(6-甲氧基吡啶-3-基)丙基]苯甲酰胺、其作为药物的用途以及包含所述化合物的药物制剂
CN100404509C (zh) 一类异喹啉化合物及其盐的制备方法和应用
CN100395236C (zh) 用于治疗神经病的哌嗪和哌啶衍生物
CN1463972A (zh) 新的n－取代吡啶基苯并异硒唑酮化合物及其制法和其药物组合物与用途
US8106099B2 (en) Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias
CN102001971A (zh) N-(4-胍基丁基)丁香酰胺衍生物及其医药用途
CN114349730B (zh) 柚皮素衍生物及其用途
EP3027190A1 (en) Compound and methods for treating long qt syndrome
US4128555A (en) 3-Phenoxypyridine monosulfate and a method for its production
US20090209767A1 (en) 2-(Butyl-1-sulfonylamino)-n-[1(R)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
Lynch et al. Cardiac electrophysiologic and antiarrhythmic actions of 3, 4-dihydro-1'-[2-(benzofurazan-5-yl) ethyl]-6-methanesulfonamidospiro [(2H)-1-benzopyran-2, 4'-piperidin]-4-one HCl (L-691,121), a novel class III agent.
TWI246508B (en) 5-(9-acridinylamino)-toluidine compounds
Bodor et al. A tryptamine analog with high affinity to the heart tissues is a potential antiarrhythmic agent
JP2012250998A (ja) イオンチャネル調節化合物の投与レジメ
CN102532009A (zh) 一种抑制二肽激肽酶的化合物及制备方法和用途
HK1086819B (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]- benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
CN106507794B (zh) 二苯羟乙巯酸二乙胺基乙酯及其盐酸盐的制备方法和其在药物中的用途
JP2007505036A (ja) フェニルカルボキサミドとβ−アドレナリン性受容体遮断剤の組み合わせおよびそれらの心房性不整脈の処置のための使用
CN101928274B (zh) 椒苯酮胺衍生物
WO2013151735A1 (en) Method to mitigate long-qt arrhythmias
WO2007053415A2 (en) Agents for the treatment of cardiac arrhythmias
JPH0826995A (ja) ベンズイミダゾール誘導体を含有する抗不整脈剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1086819

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1086819

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080116

Termination date: 20110305